Literature DB >> 17919226

Treating nonalcoholic fatty liver disease.

Nahum Méndez-Sánchez1, Marco Arrese, Daniel Zamora-Valdés, Misael Uribe.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a chronic illness with multiple consequences. The spectrum of disease ranges from simple steatosis, with benign prognosis, to a potentially progressive form, nonalcoholic steatohepatitis, which may lead to liver fibrosis and cirrhosis, leading to an increase in morbidity and mortality. Furthermore, hepatocellular carcinoma incidence in NAFLD is comparable with that observed in hepatitis C-infected patients once cirrhosis is established. Current therapy is limited to lifestyle changes and control of associated metabolic disorders; however, new treatments are on the way from basic research to bedside. A review of the current literature on treatment of nonalcoholic fatty liver disease is presented in this article.

Entities:  

Mesh:

Year:  2007        PMID: 17919226     DOI: 10.1111/j.1478-3231.2007.01567.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  8 in total

Review 1.  Thyroid hormone analogues and derivatives: Actions in fatty liver.

Authors:  Maria Coppola; Daniela Glinni; Maria Moreno; Federica Cioffi; Elena Silvestri; Fernando Goglia
Journal:  World J Hepatol       Date:  2014-03-27

Review 2.  Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.

Authors:  Juan P Arab; Roberto Candia; Rodrigo Zapata; Cristián Muñoz; Juan P Arancibia; Jaime Poniachik; Alejandro Soza; Francisco Fuster; Javier Brahm; Edgar Sanhueza; Jorge Contreras; M Carolina Cuellar; Marco Arrese; Arnoldo Riquelme
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

3.  Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways.

Authors:  Jia Xiao; Chi Tat Ho; Emily C Liong; Amin A Nanji; Tung Ming Leung; Thomas Yue Huen Lau; Man Lung Fung; George L Tipoe
Journal:  Eur J Nutr       Date:  2013-03-21       Impact factor: 5.614

4.  Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.

Authors:  Feng-Shang Zhu; Su Liu; Xi-Mei Chen; Zhi-Gang Huang; Dong-Wei Zhang
Journal:  World J Gastroenterol       Date:  2008-11-07       Impact factor: 5.742

5.  Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease.

Authors:  Jung Won Yun; Yong Kyun Cho; Jung Ho Park; Hong Joo Kim; Dong Il Park; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim
Journal:  Liver Int       Date:  2009-04       Impact factor: 5.828

6.  Effects of D-002, a mixture of high molecular weight beeswax alcohols, on patients with nonalcoholic fatty liver disease.

Authors:  José Illnait; Iván Rodríguez; Sarahí Mendoza; Yolanda Fernández; Rosa Mas; Mirtha Miranda; Jesús Piñera; Julio César Fernández; Meilis Mesa; Lilia Fernández; Daisy Carbajal; Rafael Gámez
Journal:  Korean J Intern Med       Date:  2013-07-01       Impact factor: 2.884

7.  The efficacy and safety of traditional chinese medicine (jiang zhi granule) for nonalcoholic Fatty liver: a multicenter, randomized, placebo-controlled study.

Authors:  Jielu Pan; Miao Wang; Haiyan Song; Lin Wang; Guang Ji
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-04       Impact factor: 2.629

8.  Lifestyle Intervention Enabled by Mobile Technology on Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial.

Authors:  Su Lin Lim; Jolyn Johal; Kai Wen Ong; Chad Yixian Han; Yiong Huak Chan; Yin Mei Lee; Wai Mun Loo
Journal:  JMIR Mhealth Uhealth       Date:  2020-04-13       Impact factor: 4.773

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.